11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Cameron, David, Prof, Piccart-Gebhart, Martine J, PhD, Gelber, Richard D, PhD, Procter, Marion, PhD, Goldhirsch, Aron, MD, de Azambuja, Evandro, MD, Castro, Gilberto, MD, Untch, Michael, MD, Smith, Ian, MD, Gianni, Luca, MD, Baselga, Jose, MD, Al-Sakaff, Nedal, PhD, Lauer, Sabine, PhD, McFadden, Eleanor, MA, Leyland-Jones, Brian, MBBS, Bell, Richard, MBBS, Dowsett, Mitch, PhD, Jackisch, Christian, MD
Published in The Lancet (British edition) (25.03.2017)
Published in The Lancet (British edition) (25.03.2017)
Get full text
Journal Article
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Gianni, Luca, Prof, Dafni, Urania, Prof, Gelber, Richard D, Prof, Azambuja, Evandro, PhD, Muehlbauer, Susanne, PhD, Goldhirsch, Aron, Prof, Untch, Michael, Prof, Smith, Ian, Prof, Baselga, José, Prof, Jackisch, Christian, Prof, Cameron, David, Prof, Mano, Max, MD, Pedrini, José Luiz, MD, Veronesi, Andrea, Prof, Mendiola, Cesar, MD, Pluzanska, Anna, Prof, Semiglazov, Vladimir, MD, Vrdoljak, Eduard, MD, Eckart, Michael J, MD, Shen, Zhenzhou, Prof, Skiadopoulos, George, MSci, Procter, Marion, MSci, Pritchard, Kathleen I, MD, Piccart-Gebhart, Martine J, PhD, Bell, Richard, MBBS
Published in The lancet oncology (01.03.2011)
Published in The lancet oncology (01.03.2011)
Get full text
Journal Article